Upregulated NLRP3 inflammasome activation in patients with type 2 diabetes

Diabetes

Volumn 62, Issue 1, 2013, Pages 194-204

  Lee, Hye Mi ^a   Kim, Jwa Jin ^a   Kim, Hyun Jin ^b   Shong, Minho ^a,b   Ku, Bon Jeong ^a,b   Jo, Eun Kyeong ^a  

^a Chungnam National University   (South Korea)

^b Chungnam National University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; AMYLIN; CRYOPYRIN; FATTY ACID; HIGH MOBILITY GROUP B1 PROTEIN; INFLAMMASOME; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; MESSENGER RNA; METFORMIN; MITOGEN ACTIVATED PROTEIN KINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR ALPHA; URIC ACID;

ADULT; APOPTOSIS; ARTICLE; CELL MATURATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME ACTIVATION; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN TISSUE; MACROPHAGE; MALE; MITOCHONDRION; MONOCYTE; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; UPREGULATION;

ADULT; AGED; AMP-ACTIVATED PROTEIN KINASES; CARRIER PROTEINS; CYTOSKELETAL PROTEINS; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; INFLAMMASOMES; INTERLEUKIN-18; INTERLEUKIN-1BETA; MALE; METFORMIN; MIDDLE AGED; REACTIVE OXYGEN SPECIES; RNA, MESSENGER;

EID: 84872018875     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db12-0420     Document Type: Article

References (44)

1. Centers for Disease Control and Prevention. National Diabetes Surveillance System: prevalence of diabetes. http://www.cdc.gov/diabetes/ statistics/prev/national/menuage.htm 2010
2. Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol 2011;11:98-107
3. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest 2006;116:1793-1801 (Pubitemid 44033299)
4. Ceriello A, Motz E. Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited. Arterioscler Thromb Vasc Biol 2004;24:816-823 (Pubitemid 38620857)
5. Zhou R, Tardivel A, Thorens B, Choi I, Tschopp J. Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat Immunol 2010;11:136-140
6. Pedra JH, Cassel SL, Sutterwala FS. Sensing pathogens and danger signals by the inflammasome. Curr Opin Immunol 2009;21:10-16
7. De Nardo D, Latz E. NLRP3 inflammasomes link inflammation and metabolic disease. Trends Immunol 2011;32:373-379
8. Stienstra R, Joosten LA, Koenen T, et al. The inflammasome-mediated caspase-1 activation controls adipocyte differentiation and insulin sensitivity. Cell Metab 2010;12:593-605
9. Vandanmagsar B, Youm YH, Ravussin A, et al. The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat Med 2011;17:179-188
10. Wen H, Gris D, Lei Y, et al. Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling. Nat Immunol 2011;12:408-415
11. Stienstra R, van Diepen JA, Tack CJ, et al. Inflammasome is a central player in the induction of obesity and insulin resistance. Proc Natl Acad Sci USA 2011;108:15324-15329
12. Spranger J, Kroke A, Möhlig M, et al. Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes 2003;52:812-817 (Pubitemid 36323590)
13. Jager J, Grémeaux T, Cormont M, Le Marchand-Brustel Y, Tanti JF. Interleukin-1beta-induced insulin resistance in adipocytes through downregulation of insulin receptor substrate-1 expression. Endocrinology 2007;148:241-251
14. Larsen CM, Faulenbach M, Vaag A, et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 2007;356:1517-1526 (Pubitemid 46588416)
15. Mandrup-Poulsen T, Pickersgill L, Donath MY. Blockade of interleukin 1 in type 1 diabetes mellitus. Nat Rev Endocrinol 2010;6:158-166
16. Stutz A, Golenbock DT, Latz E. In flammasomes: too big to miss. J Clin Invest 2009;119:3502-3511
17. Shaw PJ, McDermott MF, Kanneganti TD. Inflammasomes and autoimmunity. Trends Mol Med 2011;17:57-64
18. Nakahira K, Haspel JA, Rathinam VA, et al. Autophagy proteins regulate innate immune responses by inhibiting the release of mitochondrial DNA mediated by the NALP3 in flammasome. Nat Immunol 2011;12:222-230
19. Coletta DK, Mandarino LJ. Mitochondrial dysfunction and insulin resistance from the outside in: extracellular matrix, the cytoskeleton, and mitochondria. Am J Physiol Endocrinol Metab 2011;301:E749-E755
20. DeFronzo RA, Abdul-Ghani M. Type 2 diabetes can be prevented with early pharmacological intervention. Diabetes Care 2011;34(Suppl 2):S202-S209
21. WHO/IASO/IOTF, Ed. The Asia-Pacific Perspective: Redefining Obesity and Its Treatment. Melbourne, Health Communications Australia Pty Ltd, 2000
22. Lee HM, Yuk JM, Kim KH, et al. Mycobacterium abscessus activates the NLRP3 inflammasome via Dectin-1-Syk and p62/SQSTM1. Immunol Cell Biol 2012;90:601-610.
23. Yuk JM, Shin DM, Lee HM, et al. Vitamin D3 induces autophagy in human monocytes/macrophages via cathelicidin. Cell Host Microbe 2009;6:231-243
24. Dasu MR, Devaraj S, Park S, Jialal I. Increased toll-like receptor (TLR) activation and TLR ligands in recently diagnosed type 2 diabetic subjects. Diabetes Care 2010;33:861-868
25. Netea MG, Nold-Petry CA, Nold MF, et al. Differential requirement for the activation of the inflammasome for processing and release of IL-1beta in monocytes and macrophages. Blood 2009;113:2324-2335
26. Zhou R, Yazdi AS, Menu P, Tschopp J. A role for mitochondria in NLRP3 inflammasome activation. Nature 2011;469:221-225
27. Herlein JA, Fink BD, O'Malley Y, Sivitz WI. Superoxide and respiratory coupling in mitochondria of insulin-deficient diabetic rats. Endocrinology 2009;150:46-55
28. Boyle JG, Logan PJ, Jones GC, et al. AMP-activated protein kinase is activated in adipose tissue of individuals with type 2 diabetes treated with metformin: a randomised glycaemia-controlled crossover study. Diabetologia 2011;54:1799-1809
29. Lee MS. Role of innate immunity in diabetes and metabolism: recent progress in the study of inflammasomes. Immune Netw 2011;11:95-99
30. Masters SL, Latz E, O'Neill LAJ. The inflammasome in atherosclerosis and type 2 diabetes. Sci Transl Med 2011;3:81ps17
31. Hoffman HM, Mueller JL, Broide DH, Wanderer AA, Kolodner RD. Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. Nat Genet 2001;29:301-305 (Pubitemid 33096455)
32. Wagner H. Endogenous TLR ligands and autoimmunity. Adv Immunol 2006;91:159-173 (Pubitemid 44286996)
33. Drummond GR, Selemidis S, Griendling KK, Sobey CG. Combating oxidative stress in vascular disease: NADPH oxidases as therapeutic targets. Nat Rev Drug Discov 2011;10:453-471
34. Rains JL, Jain SK. Oxidative stress, insulin signaling, and diabetes. Free Radic Biol Med 2011;50:567-575
35. Colombini M. VDAC: the channel at the interface between mitochondria and the cytosol. Mol Cell Biochem 2004;256-257:107-115 (Pubitemid 38181239)
36. Bulua AC, Simon A, Maddipati R, et al. Mitochondrial reactive oxygen species promote production of proinflammatory cytokines and are elevated in TNFR1-associated periodic syndrome (TRAPS). J Exp Med 2011;208:519-533
37. Naik E, Dixit VM. Mitochondrial reactive oxygen species drive proinflammatory cytokine production. J Exp Med 2011;208:417-420
38. Musi N, Hirshman MF, Nygren J, et al. Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. Diabetes 2002;51:2074-2081 (Pubitemid 34729010)
39. Zheng Z, Chen H, Li J, et al. Sirtuin 1-mediated cellular metabolic memory of high glucose via the LKB1/AMPK/ROS pathway and therapeutic effects of metformin. Diabetes 2012;61:217-228
40. Viollet B, Guigas B, Sanz Garcia N, Leclerc J, Foretz M, Andreelli F. Cellular and molecular mechanisms of metformin: an overview. Clin Sci (Lond) 2012;122:253-270
41. Tan BK, Heutling D, Chen J, et al. Metformin decreases the adipokine vaspin in overweight women with polycystic ovary syndrome concomitant with improvement in insulin sensitivity and a decrease in insulin resistance. Diabetes 2008;57:1501-1507
42. Grenader T, Goldberg A, Shavit L. Metformin as an addition to conventional chemotherapy in breast cancer. J Clin Oncol 2009;27:e260
43. Joya-Galeana J, Fernandez M, Cervera A, et al. Effects of insulin and oral anti-diabetic agents on glucose metabolism, vascular dysfunction and skeletal muscle inflammation in type 2 diabetic subjects. Diabetes Metab Res Rev 2011;27:373-382
44. Zmijewski JW, Lorne E, Zhao X, et al. Mitochondrial respiratory complex I regulates neutrophil activation and severity of lung injury. Am J Respir Crit Care Med 2008;178:168-179 (Pubitemid 351957775)